Impact of Glaucoma and Visual Field Loss on Life Space

Sponsor
University of Alabama at Birmingham (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03673644
Collaborator
National Institute on Aging (NIA) (NIH)
88
1
55.7
1.6

Study Details

Study Description

Brief Summary

Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaires

Detailed Description

Aim 1: To examine the extent of life space in older adults with POAG using the Life Space Questionnaire and to examine whether life space in persons with POAG is associated with the magnitude of visual field impairment.

Aim 2: To examine difficulties seeing under dim illumination and at night in older adults with POAG using the Low Luminance Questionnaire and to examine whether greater difficulty in seeing under dim illumination and at night is related to the magnitude of visual field loss.

Aim 3: To examine the relationship in older adults with POAG between visual problems seeing under dim illumination and at night (Low Luminance Questionnaire) and their life space (Life Space Questionnaire).

Study Design

Study Type:
Observational
Anticipated Enrollment :
88 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Actual Study Start Date :
Oct 9, 2018
Actual Primary Completion Date :
May 30, 2019
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Primary Open-Angle Glaucoma

Two following two questionnaires will be administered: Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame. Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.

Other: Questionnaires
Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.

Outcome Measures

Primary Outcome Measures

  1. Assessment of life space measured with the Life Space Questionnaire [Day one]

    The Life Space Questionnaire is a 9-item questionnaire that assesses how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame. Patients are asked to respond either Yes or No.

Secondary Outcome Measures

  1. Relationship between the Life Space Questionnaire and vision loss [Day one]

    The results obtained on the Life Space Questionnaire will be correlated with the results of the visual field tests

  2. Assessment of vision under dim illumination and at night using the Low Luminance Questionnaire [Day one]

    The Low Luminance Questionnaire is a 32-item questionnaire that assesses problems that involve vision under different lighting conditions or feelings about vision under different lighting conditions. The range of responses is different for different questions, with the overall pattern being that "1" means "No difficulty at all" and that increasingly higher numbers mean increasingly more difficulty.

  3. Relationship between Low Luminance Questionnaire and vision loss [Day one]

    The results obtained on the Low Luminance Questionnaire will be correlated with the results of the visual field tests.

  4. Relationship between the Low Luminance Questionnaire and the Life Space Questionnaire [Day one]

    The results of the Low Luminance Questionnaire will be correlated with the results of the Life Space Questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of primary open-angle glaucoma

  • Best-corrected visual acuity of 20/40 or better

  • Spherical refraction within ± 5 Diopters

  • Cylinder refraction within ± 3 Diopters

Exclusion Criteria:
  • History of intra-ocular surgery other than uncomplicated cataract or glaucoma surgery

  • Significant cognitive impairment

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alabama at Birmingham Birmingham Alabama United States 35294

Sponsors and Collaborators

  • University of Alabama at Birmingham
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Lyne Racette, PhD, University of Alabama at Birmingham

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lyne Racette, Principal Investigator, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT03673644
Other Study ID Numbers:
  • IRB-300001552
  • 5P30AG022838-14
First Posted:
Sep 17, 2018
Last Update Posted:
Aug 9, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2021